Where can I listen to this podcast?

This podcast is available on 4 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.

Does this podcast accept guests?

Yes, this podcast regularly features guests.

R2 IP

Claim This Podcast

by Raymond Miller

5.0(4 reviews)

7 episodes

Updated Daily

Accepts GuestsHas SponsorsLocation 🇺🇸

Podcast Overview

🎙️ The R² IP Podcast, hosted by Ray Miller, explores the intersection of law, science, and innovation. Ray is the US Chair of DLA Piper’s Life Sciences Patent Development & Strategy group and a trusted advisor to pharmaceutical, biotech, and technology companies. He has guided billion-dollar investments, extended patent exclusivity for portfolios valued at more than half a billion dollars, and built trade-secret programs strong enough to defeat high-stakes misappropriation claims. Each episode shows how intellectual capital—ideas, discoveries, and breakthroughs—can be transformed into intellectual property (IP) that protects, powers, and propels businesses forward. Ray’s work includes crafting regulatory exclusivity strategies where no composition-of-matter patents exist, securing freedom-to-operate for product launches, and navigating the International Trade Commission in complex infringement disputes—all experiences that bring a sharp, real-world perspective to every conversation. With a focus on life sciences, biotech, technology, and AI, the show delivers insights on patents, trade secrets, licensing, litigation, and strategy. Featuring thought leaders, investors, and innovators, the R² IP Podcast offers both practical guidance and strategic vision to entrepreneurs, executives, and professionals navigating today’s fast-moving innovation economy. ✨ What you’ll hear: • How to turn cutting-edge research into enforceable IP assets • Patent trends reshaping biotech, pharma, and emerging tech • Strategies for protecting innovation in an AI-driven world • Lessons from landmark cases and global IP developments • Real-world insights from the frontlines of law, science, and business R² stands for “best fit”—and this podcast is the best fit for anyone looking to align IP strategy with business success. 📌 Recognitions & Thought Leadership • Recognized by Chambers USA and The Legal 500 as a leading IP lawyer in licensing and patent strategy • Named an Acritas Star and listed in Patent 1000 and Strategy 300 by International Asset Management • Published widely on IP issues in outlets such as Bloomberg Law, Law360, IPWatchdog, and The Licensing Journal • Frequent speaker at industry conferences and summits on protecting innovation, commercializing biotech breakthroughs, and aligning IP with investment strategy Reach out to Ray Miller at raymond.miller@us.dlapiper.com for inquiries or opportunities to join the conversation.

Language

🇺🇲

Publishing Since

8/19/2025

View on Apple Podcasts RSS Feed

1 verified contact email on file for R2 IP

Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.

See contact details

Recent Episodes

December 1, 2025

Building a Biotech From Zero (Part 2 of 2): Investor Reality, Liquidity Myths & Founder Dynamics

In Part 2, Ray and David continue their deep dive into the realities of early-stage biotech growth—moving into warrant coverage, investor upside, dilution, and the often-overlooked truth that early equity can be illiquid for years. David breaks down liquidation waterfalls, down rounds, fiduciary duties, and what happens when a company approaches insolvency. They close with a candid look at managing founder relationships, avoiding “dead equity,” and keeping the company aligned when the science, money, and people all collide. <ul><li>01:43 Understanding Conversion Discounts</li><li>02:07 Negotiation Points and Valuation</li><li>03:11 Enterprise Value and Share Price</li><li>04:37 Impact on Founders' Equity</li><li>08:47 Capital Gains Tax Benefits</li><li>13:47 Liquidity and Exit Strategies</li><li>19:07 Investor Motivations and Risks</li><li>34:20 Board and Management Obligations</li><li>43:11 Ray's Retreat Overview</li></ul>

November 26, 2025

Building a Biotech From Zero (Part 1 of 2): Formation, Founders & First Money In

In Part 1 of this two-episode conversation, Ray sits down with longtime partner and life-sciences attorney David Smith to unpack the earliest—and most misunderstood—moments in forming a biotech company. They dive into choosing the right corporate structure, splitting founder equity, why timing matters, and how early financing tools like convertible notes and SAFEs really work. It’s a clear, practical look at the decisions that quietly determine whether a life sciences startup ever gets off the ground. It’s candid, practical, and full of the small details only 30 years of trenches-level experience can give you.

November 5, 2025

Stacking Exclusivity: How Regulatory Incentives Power Drug Innovation

A pharmacist–turned–regulatory strategist and a 25-year patent attorney walk into a podcast… and blow up the myth that “no composition of matter means no value.” <ul><li>Ray and Nicole break down how regulatory exclusivity actually drives drug innovation, often more powerfully than patents.</li><li>Hear how NCE, orphan drug, pediatric, and GAIN Act exclusivity can turn an old or overlooked molecule into a fundable, defensible asset.</li><li>Discover why biologics play by completely different rules, why there’s no Orange Book, and what the mysterious “patent dance” really is.</li><li>Learn how exclusivities can stack (and when they absolutely don’t), including real examples of companies turning five years into ten—or more.</li><li>Get a preview of skinny labeling, the loophole that stops perpetual exclusivity and deserves its own episode.</li><li>Plus: a rapid tour of EU, China, and Japan exclusivity systems and how global rights shape investment strategy.</li></ul> A fast, clear, myth-busting guide to one of the most misunderstood forces in the life sciences industry.

7 total episodes available

Deep-dive analytics for R2 IP

Frequently asked questions

Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.

What is R2 IP?: 🎙️ The R² IP Podcast, hosted by Ray Miller, explores the intersection of law, science, and innovation. Ray is the US Chair of DLA Piper’s Life Sciences Patent Development & Strategy group and a trusted advisor to pharmaceutical, biotech, and technology companies. He has guided billion-dollar investments, extended patent exclusivity for portfolios valued at more than half a billion dollars, and built trade-secret programs strong enough to defeat high-stakes misappropriation claims. Each episode shows how intellectual capital—ideas, discoveries, and breakthroughs—can be transformed into intellectual property (IP) that protects, powers, and propels businesses forward. Ray’s work includes crafting regulatory exclusivity strategies where no composition-of-matter patents exist, securing freedom-to-operate for product launches, and navigating the International Trade Commission in complex infringement disputes—all experiences that bring a sharp, real-world perspective to every conversation. With a focus on life sciences, biotech, technology, and AI, the show delivers insights on patents, trade secrets, licensing, litigation, and strategy. Featuring thought leaders, investors, and innovators, the R² IP Podcast offers both practical guidance and strategic vision to entrepreneurs, executives, and professionals navigating today’s fast-moving innovation economy. ✨ What you’ll hear: • How to turn cutting-edge research into enforceable IP assets • Patent trends reshaping biotech, pharma, and emerging tech • Strategies for protecting innovation in an AI-driven world • Lessons from landmark cases and global IP developments • Real-world insights from the frontlines of law, science, and business R² stands for “best fit”—and this podcast is the best fit for anyone looking to align IP strategy with business success. 📌 Recognitions & Thought Leadership • Recognized by Chambers USA and The Legal 500 as a leading IP lawyer in licensing and patent strategy • Named an Acritas Star and listed in Patent 1000 and Strategy 300 by International Asset Management • Published widely on IP issues in outlets such as Bloomberg Law, Law360, IPWatchdog, and The Licensing Journal • Frequent speaker at industry conferences and summits on protecting innovation, commercializing biotech breakthroughs, and aligning IP with investment strategy Reach out to Ray Miller at raymond.miller@us.dlapiper.com for inquiries or opportunities to join the conversation.
How often does this podcast release new episodes?: This podcast updates daily.
Where can I listen to this podcast?: This podcast is available on 4 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
Does this podcast accept guests?: Yes, this podcast regularly features guests.

Legal Disclaimer

Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.

All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.

We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.

While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.

By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.